Why the study?
The study evaluated the efficacy of SGLT2 inhibitors in reducing key cardiovascular outcomes in patients with heart failure with reduced ejection fraction under contemporary standard care.
Do SGLT2 inhibitors reduce cardiovascular mortality, heart failure hospitalization, and all-cause mortality in patients with HFrEF compared to standard care?
Do SGLT2 inhibitors reduce cardiovascular mortality, heart failure hospitalization, and all-cause mortality in patients with HFrEF compared to standard care?
SGLT2 inhibitors significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with HFrEF regardless of diabetes status, supporting their routine integration into standard care.
Answers are grounded in this paper and cite their sources.
Strengthens SGLT2i as first-line HFrEF therapy; confirms consistent reductions in HF hospitalization and mortality across RCTs.
This systematic literature review and meta-analysis evaluates the efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in reducing key cardiovascular outcomes, namely hospitalization for heart failure, cardiovascular mortality, and all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF). A total of 12 publications (including subgroup analyses) were analyzed. The selected RCTs compared the effects of SGLT2i (empagliflozin, dapagliflozin, and canagliflozin) with standard care among patients with HFrEF. The pooled data demonstrated that SGLT2i significantly reduced the risk of cardiovascular mortality by 23% and hospitalization for heart failure by 25%, compared to standard care. These benefits were consistently observed across both diabetic and non-diabetic subgroups, underscoring the broader therapeutic potential of SGLT2i in HFrEF management. However, no statistically significant reduction in all-cause mortality was identified. While the findings affirm the cardioprotective effects of SGLT2i, the lack of impact on overall mortality highlights the need for further longitudinal studies. These results support the integration of SGLT2i into contemporary HFrEF treatment protocols while informing future research priorities.
No takes yet. Share an insight, caveat, or question.
Makhsham et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: